CJC-1295 – GHRH Analog Research Summary

CJC-1295 – GHRH Analog Research Summary

Peptide Research Documentation · For Research Use Only

Peptide Research Documentation

CJC-1295 – Research Documentation Overview

Neutral, research-only summary for laboratories and qualified organizations exploring growth hormone-releasing hormone (GHRH) analog compounds in non-clinical models.

For Research Use Only. CJC-1295 (Sermorelin analog, tetrasubstituted GHRH(1-29) with D-Ala substitutions and Lys^27-PAL conjugate) is a synthetic 30-amino-acid peptide intended exclusively for in vitro and non-clinical in vivo research. This compound is not approved for human consumption, medical use, or veterinary application.

At a Glance

CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH) engineered through four D-amino acid substitutions and C-terminal Lys^27 conjugation with a proprietary drug affinity complex (DAC) moiety. These modifications extend plasma half-life from minutes (native GHRH) to days or weeks, enabling less frequent dosing in research applications. Published literature demonstrates robust, sustained GH secretion in rodent and primate models with preserved somatotroph responsiveness over extended dosing periods. The 30-amino-acid backbone provides selectivity for GHRH receptor (GHRHR) with minimal off-target activity.

Document Objectives

  • Define molecular structure, GHRHR selectivity, and mechanism of extended half-life
  • Establish storage parameters, stability windows, and reconstitution best practices
  • Outline documentation, traceability, and regulatory compliance standards
  • Review representative non-clinical models: GH secretion, body composition, neuroendocrine aging
  • Address risk assessment, analytical purity, and institutional oversight requirements

Storage & Stability

Recommended Storage Conditions

CJC-1295 lyophilized powder exhibits optimal stability when stored at -20°C to -80°C in airtight, opaque (amber) vials or containers. For extended research programs (≥12 months), -80°C freezer storage is strongly recommended. The 30-amino-acid GHRH backbone with engineered D-amino acid substitutions and DAC conjugate provides substantial resistance to serum protease degradation but does not confer protection against oxidative degradation or hydrolysis at room temperature. Storage above 0°C accelerates peptide cross-linking and disulfide bond rearrangement.

Lyophilized Product Characteristics

Unopened CJC-1295 vials in original packaging maintain potency for 24 months at -20°C and typically 36+ months at -80°C (per manufacturer stability data). Upon receipt, confirm powder appearance: a white to off-white lyophilisate is expected. Visible discoloration (tan, brown, yellow tinting) or moisture clumping indicates prior temperature excursion or humidity exposure and warrants rejection. Once reconstituted in sterile saline or PBS, working solutions (0.05–5 mM) remain viable for 2–4 weeks at 4°C under aseptic conditions in protein-low-binding vessels.

Environmental Protection & Preservation Strategies

Store containers in desiccated environments using vacuum-sealed bags or molecular sieve desiccant packs. Minimize light exposure through amber vials or foil wrapping. Maintain relative humidity <50% during storage to prevent hygroscopic moisture absorption. Use low-protein-binding polypropylene or siliconized glass vessels for long-term reconstituted solutions. Avoid repeated freeze-thaw cycles; instead, prepare small aliquots for single use and discard unused portions immediately after thawing.

Handling & Aliquoting

Preparation & Dissolution Protocol

Weigh CJC-1295 lyophilized powder using a calibrated analytical balance (±0.001 g precision). Dissolve in sterile, endotoxin-free saline (0.9% NaCl), 1× PBS (pH 7.4), or cell culture medium (Neurobasal, DMEM) depending on experimental context. Allow 30–45 minutes at ambient temperature for complete dissolution, gently mixing or vortexing as needed; avoid heating, which accelerates peptide thermal denaturation and disulfide bond rearrangement. For animal dosing solutions, use USP-grade parenteral vehicles (sterile water for injection, normal saline) prepared under strict aseptic conditions.

Aliquoting & Inventory Control

Prepare stock solutions (0.1–5 mM) and divide into sterile, low-protein-binding microtubes (50–500 μL per aliquot) using laminar flow hood aseptic technique. Label each tube with: compound name (CJC-1295), lot number, date of preparation, final concentration, and expiration date. Working solutions for animal dosing should be prepared fresh or stored at 4°C for a maximum of 72 hours. Maintain a master aliquot inventory in both electronic and hardcopy formats, documenting all uses, final dispositions, and responsible researchers.

Aseptic Handling Best Practices

All preparation of CJC-1295 solutions must comply with GLP aseptic technique standards. Use only sterile, pyrogen-free pipette tips, microtubes, and syringes. For subcutaneous or intravenous administration, filter-sterilize solutions through 0.22 μm syringe filters immediately before dosing. Inspect all prepared solutions for particulates, cloudiness, or discoloration; discard any compromised batches. Store prepared solutions in low-protein-binding vessels (polypropylene, siliconized glass) to prevent absorption of the long GHRH peptide backbone. Document final volumes, concentrations, and any observations of visual or olfactory changes.

Documentation Checklist

Essential Records & Certifications

Archival & Ongoing Compliance

Maintain dual archival of all CoAs, quality assurance certificates, and analytical reports in both secure hardcopy and encrypted electronic formats. For studies exceeding 8 weeks, perform periodic potency verification (HPLC-UV analysis or bioassay) of stored working solutions to rule out degradation. Document any deviations from expected visual appearance, odor, or solubility and initiate root-cause analysis investigations.

Example Non-Clinical Models

Acute & Chronic GH Secretion in Rodents

CJC-1295 (0.1–10 μg/kg, SC injection) stimulates dose-dependent GH secretion in rats and mice with a prolonged plasma half-life (4–6 hours in rodents, days in primates) compared to native GHRH. Single-dose studies employ frequent blood sampling (q15 min for 2–4 hours) to characterize GH release kinetics. Chronic dosing protocols (0.5–10 μg/kg, 3×/week or daily for 4–16 weeks) maintain elevated baseline GH and restore GH pulse frequency and amplitude in aged or GH-deficient rodent models.

Body Composition & Metabolic Effects

Long-term CJC-1295 administration (0.1–5 μg/kg, 3–7×/week for 8–24 weeks) in rodent obesity models, aging studies, and GH-deficient transgenic models has been evaluated for effects on lean mass accretion, fat mass reduction, serum IGF-1 elevation, and metabolic improvements (insulin sensitivity, glucose homeostasis). Representative models include diet-induced obesity, Zucker fa/fa rats, aged (18–24 month) Fisher-344 rats, and GH-deficient dwarf mice. Outcomes include MRI-derived body composition, indirect calorimetry, serum biochemistry, and necropsy-based organ analysis.

Somatotroph Responsiveness in Aging & Disease

Repeated CJC-1295 dosing has been studied for preservation of somatotroph sensitivity and restoration of GH pulse architecture in accelerated aging models, metabolic disease (diabetes, obesity), and pharmacologically-induced GH deficiency. Studies employ high-frequency blood sampling (q10–15 min, 6–12 hour periods) and deconvolution analysis to quantify GH pulse parameters (pulse frequency, amplitude, interpulse nadir). Pituitary explant culture systems assess GH secretory capacity and GHRHR expression changes.

Neuroendocrine & Reproductive Function

CJC-1295 effects on hypothalamic-pituitary-gonadal (HPG) axis function have been evaluated in reproductive senescence models and GH-deficient disease contexts. Studies assess GnRH release (via pulsatile luteinizing hormone [LH] secretion), testosterone and estradiol levels, and reproductive organ histology. In combination with sex hormone-releasing peptides, CJC-1295 has been evaluated for synergistic restoration of reproductive function in aged animals.

Compliance & Risk Notes

Regulatory & Legal Status

CJC-1295 is not approved by the FDA, EMA, PMDA, or other major regulatory authorities for human or animal therapeutic use. No marketed pharmaceutical products contain CJC-1295 or its DAC-conjugate variant. As a research-grade compound, it falls outside GMP pharmaceutical frameworks but should be procured from suppliers maintaining GLP-aligned quality standards, validated analytical methods, and comprehensive documentation infrastructure. Academic and contract research organizations using CJC-1295 must establish GLP-compatible operational SOPs for studies that may support regulatory filings.

Safety Considerations & Hazard Profile

CJC-1295 lyophilized powder presents minimal acute inhalation, dermal, or ocular hazard at typical laboratory quantities. Aqueous solutions are non-irritating to mucous membranes at physiological concentrations (≤100 μM). Standard laboratory PPE (nitrile gloves, laboratory coat) and engineering controls (fume hood for weighing) provide appropriate protection. In animal studies, subcutaneous injection carries routine risks (localized irritation, sterile abscess formation); strict aseptic technique, use of sterile graduated syringes, and visual injection site monitoring minimize adverse events. The long-acting nature of CJC-1295 (DAC conjugate) means residual systemic effects may persist for days post-dosing; this should be considered when designing washout periods between treatment and study endpoint assessments.

Data Integrity & Research Oversight

Establish comprehensive written SOPs for CJC-1295 receipt, storage, reconstitution, animal dosing, and archival. Implement unique lot tracking identifiers for all compound batches and aliquots. Maintain synchronized hardcopy and electronic records documenting all compound use, with clear chain-of-custody linking lot numbers to specific experiments and publications. Ensure IACUC protocol approval for all animal studies and maintain compliance with institutional animal care standards. Archive all research data (raw datasets, analysis reports, final manuscripts) for a minimum of 7 years to support regulatory audit readiness if studies contribute to IND submissions or preclinical regulatory dossiers.

References & Evidence Snapshot

Key Scientific Literature

Evidence Summary

CJC-1295 is an extensively published, second-generation GHRH analog with robust preclinical evidence supporting sustained GH secretion and preservation of somatotroph responsiveness in rodent, canine, and primate models. The drug affinity complex (DAC) conjugation strategy dramatically extends plasma half-life from minutes (native GHRH, analog sermorelin) to hours or days, enabling less frequent dosing schedules and sustained GH elevation in chronic research contexts. Key advantages include receptor selectivity for GHRHR with minimal off-target prolactin or cortisol stimulation, and superior pharmacological durability compared to unconjugated GHRH analogs. Body composition and metabolic studies in aging and disease models support CJC-1295’s utility for investigating sustained GH effects on lean mass accretion, fat mass reduction, and insulin sensitivity, though translation of rodent findings to human GH biology requires careful consideration of species-specific somatotroph aging, GHRHR expression patterns, and IGF-1-dependent metabolic compensation mechanisms.

← Back to Peptide Research Index

Questions About This Compound?

Our clinical team can help with research documentation and protocol guidance.

Contact Our Team

Disclaimer: This content is for research documentation purposes only. Not for human consumption or therapeutic application.

GLP3 Weight Loss

Customer Support

Get in touch with our team today.

  • +1757-618-2938
  • info@glp3weightloss.com

    Get Update & More

    Subscribe to our free newsletter and get 15% discount in your next order.

    SIGN UP NOW

    Copyright © 2025 GLP3 Weight Loss.